Final congressional passage of the Food and Drug Administration (FDA) Safety and Innovation Act is expected to renew interest in antibiotic research and development.
The legislation (S 3187; http://tinyurl.com/7kz57hk) primarily requires drug and device manufacturers to pay user fees to fund the FDA's approval process for drugs and medical devices. But some of the fees are earmarked to bolster the agency's safety oversight and to pay for other programs, such as creating incentives for antibiotic development.
Mitka M. Incentives for New Antibiotics. JAMA. 2012;308(6):558. doi:10.1001/jama.2012.9558
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: